Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa. / Yao, Yiqiu; Jorgensen, Astrid-Helene Ravn; Nielsen, Valdemar Wendelboe; Egeberg, Alexander; Thyssen, Jacob P.; Thomsen, Simon Francis.

In: Drugs of the Future, Vol. 47, No. 8, 08.2022, p. 567-573.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Yao, Y, Jorgensen, A-HR, Nielsen, VW, Egeberg, A, Thyssen, JP & Thomsen, SF 2022, 'Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa', Drugs of the Future, vol. 47, no. 8, pp. 567-573. https://doi.org/10.1358/dof.2022.47.8.3435135

APA

Yao, Y., Jorgensen, A-H. R., Nielsen, V. W., Egeberg, A., Thyssen, J. P., & Thomsen, S. F. (2022). Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa. Drugs of the Future, 47(8), 567-573. https://doi.org/10.1358/dof.2022.47.8.3435135

Vancouver

Yao Y, Jorgensen A-HR, Nielsen VW, Egeberg A, Thyssen JP, Thomsen SF. Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa. Drugs of the Future. 2022 Aug;47(8):567-573. https://doi.org/10.1358/dof.2022.47.8.3435135

Author

Yao, Yiqiu ; Jorgensen, Astrid-Helene Ravn ; Nielsen, Valdemar Wendelboe ; Egeberg, Alexander ; Thyssen, Jacob P. ; Thomsen, Simon Francis. / Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa. In: Drugs of the Future. 2022 ; Vol. 47, No. 8. pp. 567-573.

Bibtex

@article{ba60ffe8f84c4650838d2a8ab5c6a38a,
title = "Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa",
abstract = "Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.",
keywords = "IL-17, Monoclonal antibody, Nanobody, Psoriasis, Sonelokimab, M-1095, SEVERE PLAQUE PSORIASIS, DOUBLE-BLIND, MULTICENTER, EFFICACY, SAFETY, BIMEKIZUMAB, MECHANISMS, FAMILY, SHARK",
author = "Yiqiu Yao and Jorgensen, {Astrid-Helene Ravn} and Nielsen, {Valdemar Wendelboe} and Alexander Egeberg and Thyssen, {Jacob P.} and Thomsen, {Simon Francis}",
year = "2022",
month = aug,
doi = "10.1358/dof.2022.47.8.3435135",
language = "English",
volume = "47",
pages = "567--573",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "8",

}

RIS

TY - JOUR

T1 - Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa

AU - Yao, Yiqiu

AU - Jorgensen, Astrid-Helene Ravn

AU - Nielsen, Valdemar Wendelboe

AU - Egeberg, Alexander

AU - Thyssen, Jacob P.

AU - Thomsen, Simon Francis

PY - 2022/8

Y1 - 2022/8

N2 - Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.

AB - Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.

KW - IL-17

KW - Monoclonal antibody

KW - Nanobody

KW - Psoriasis

KW - Sonelokimab

KW - M-1095

KW - SEVERE PLAQUE PSORIASIS

KW - DOUBLE-BLIND

KW - MULTICENTER

KW - EFFICACY

KW - SAFETY

KW - BIMEKIZUMAB

KW - MECHANISMS

KW - FAMILY

KW - SHARK

U2 - 10.1358/dof.2022.47.8.3435135

DO - 10.1358/dof.2022.47.8.3435135

M3 - Journal article

VL - 47

SP - 567

EP - 573

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 8

ER -

ID: 317739663